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Abstract
Background: Although chemotherapy saves lives, increasing evidence shows that chemotherapy accelerates aging.
We previously demonstrated that mRNA expression of p16INK4a, a biomarker of senescence and molecular aging, increased
early and dramatically after beginning adjuvant anthracycline-based regimens in early stage breast cancer patients. Here,
we determined if changes in p16INK4a expression vary by chemotherapy regimen among early stage breast cancer patients.
Methods: We conducted a study of stage I-III breast cancer patients receiving adjuvant or neoadjuvant chemotherapy.
p16INK4a expression was analyzed prechemotherapy and postchemotherapy (median 6.2 months after the last chemotherapy)
in peripheral blood T lymphocytes. Chemotherapy-induced change in p16INK4a expression was compared among regimens.
All statistical tests were 2-sided. Results: In 146 women, chemotherapy was associated with a statistically significant increase
in p16INK4a expression (accelerated aging of 17 years; P < .001). Anthracycline-based regimens were associated with the largest
increases (accelerated aging of 23 to 26 years; P  .008). Nonanthracycline-based regimens demonstrated a much smaller in-
crease (accelerated aging of 9 to 11 years; P  .15). In addition to the type of chemotherapy regimen, baseline p16INK4a levels,
but not chronologic age or race, were also associated with the magnitude of increases in p16INK4a. Patients with lower p16INK4a
levels at baseline were more likely to experience larger increases. Conclusions: Our findings suggest that the aging effects of
chemotherapy may be influenced by both chemotherapy type and the patient’s baseline p16INK4a level. Measurement of
p16INK4a expression is not currently available in the clinic, but nonanthracycline regimens offering similar efficacy as
anthracycline regimens might be favored.
There is increasing evidence that cancer treatment, especially
chemotherapy, accelerates human aging (1-4). The most com-
pelling evidence comes from childhood cancer survivorship
studies that found that by age 50 years the cumulative inci-
dence of at least 1 severe, disabling, or life-threatening condi-
tion was 53.6%. In addition, 30% of survivors who reached age
35 years without any severe or life-threatening condition devel-
oped a life-threatening condition within 10 years (5).
Accumulation of chronic diseases due to accelerated aging led
to an 8.4-fold increased risk of death compared with the general
population.
Senescence is a cellular mechanism that is activated in re-
sponse to stress and DNA damage and promotes permanent in-
hibition of the cell cycle of damaged cells. This targeted control
of the cell cycle serves as a protective mechanism essential for
minimizing the proliferation of damaged cells that can lead to
tumor initiation and growth (6). Over time (or after repeated
damage), an accumulation of senescent cells in tissues contrib-
utes to perturbations in the ability of tissues to undergo repair,
in part because of the decline in the replicative function of
self-renewing stem cells and an increase in local inflammation
(7-10). Therefore, although senescent cells protect tissues from
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becoming cancerous, the accumulation of senescent cells pro-
motes chronic inflammation, declines in organ function, and
acceleration of age-related diseases (eg, atherosclerosis, idio-
pathic lung fibrosis, osteoarthritis, bone loss, hepatic steatosis,
and cognitive decline) (11).
Finding biomarkers of aging that capture changes over the
entire lifespan and reflect the clinical aspects of aging is a rich
and expanding area of research (12,13). Potential biomarkers in-
clude inflammatory markers, telomere length (14-18), sarcope-
nia, DNA methylation (19,20), and maximal oxygen
consumption (vO2max) (21). Expression of p16INK4a, a biomarker
of senescence, is considered a fundamental and dynamic mea-
surement of molecular aging with a 10-fold increase in gene ex-
pression between ages 20 and 80 years (22). p16INK4a is a tumor
suppressor molecule that acts to arrest cell proliferation, result-
ing in multi-organ cell senescence in murine models (23).
Maintenance of the p16INK4a transcript is required for mainte-
nance of the senescent phenotype, and senescent cells remain
in tissues indefinitely (24-27).
In humans, p16INK4a expression can be readily measured in T
cells and is a robust marker of age in normal controls (28).
Expression of p16INK4a in human T cells is influenced by a variety
of age-promoting stimuli, including cigarette smoking, physical
inactivity (28), cytotoxic chemotherapy administration (29),
chronic HIV infection (30), and bone marrow transplantation (4).
We previously reported rapid and persistent increases in p16INK4a
mRNA expression in the peripheral blood T cells in a small cohort
of women receiving anthracycline-based adjuvant chemotherapy
for early stage breast cancer, whereas in a second cohort of early
stage breast cancer patients who did not receive chemotherapy,
p16INK4a expression levels were similar to healthy volunteers (29).
Our initial study of chemotherapy-induced aging was done
in early stage breast cancer patients, almost all of whom re-
ceived anthracycline-based regimens (29). In the current study,
we postulated that currently used chemotherapy regimens con-
taining agents with different mechanisms of action would differ
in their propensity to induce senescence in T cells. To address
this question, we evaluated if chemotherapy-induced changes
in p16INK4a mRNA expression differed among 4 commonly used
adjuvant chemotherapy regimens. We also examined the con-
tribution of different patient and clinical characteristics, includ-
ing chronologic age and baseline p16INK4a expression, in
predicting the magnitude of increased p16INK4a expression in re-
sponse to chemotherapy treatment.
Methods
Study Participants
Patients were recruited between April 2011 and August 2018
from university-affiliated hospitals. Women aged 21 years or
older with histologically confirmed stage I-III breast cancer and
scheduled for adjuvant or neoadjuvant chemotherapy were of-
fered participation in 3 Lineberger Comprehensive Cancer
Center (LCCC) studies: LCCC1027 (NCT01305954), LCCC1334
(NCT02167932), and LCCC1410 (NCT02328313). The protocols dif-
fered in age criteria for inclusion (LCCC1334 for women aged 21
to 64 years, LCCC1410 for women aged 65 years or older,
LCCC1027 for women aged 18 years or older). All studies were
approved by the University of North Carolina at Chapel Hill
(UNC) LCCC protocol review committee and the institutional re-
view boards of each study site. Written informed consent meet-
ing all university and federal guidelines were obtained from
each participant. A total of 19, 75, and 52 participants were en-
rolled in LCCC1027, LCCC1334, and LCCC1410, respectively.
Chemotherapy Regimens
Patients enrolled in these studies received chemotherapy as de-
termined by their oncologist based on tumor stage and breast
cancer phenotype as suggested by National Comprehensive
Cancer Network guidelines (31). For statistical analysis, regimens
were arranged into 4 groups: 1) doxorubicin, cyclophosphamide,
and paclitaxel (AC-T); 2) docetaxel and cyclophosphamide 6
anti-HER2 therapy (TC); 3) docetaxel and carboplatin þ anti-HER2
therapy (TCH); and 4) doxorubicin and cyclophosphamide plus
paclitaxel and carboplatin (AC-TC). Granulocyte colony-
stimulating factors (pegfilgrastim) were routinely used in
patients receiving docetaxel and cyclophosphamide, docetaxel
and carboplatin, and doxorubicin and cyclophosphamide (when
administrated every 2 weeks—“dose dense”). For patients on
chemotherapy regimens that included anti-HER2 therapy for
12 months, postchemotherapy blood draws were done while
patients were still receiving anti-HER2 therapy.
p16INK4a Assay
Blood samples were drawn prior to chemotherapy initiation and
at least 60 days after the completion of chemotherapy. The me-
dian time from the last chemotherapy treatment to the postche-
motherapy blood sample was 6.2 months (range ¼ 2.1-14.3). Blood
was drawn into lavender-top EDTA tubes, T cells were isolated,
and expression of p16INK4a mRNA in peripheral blood
T lymphocytes was determined using TaqMan real-time quanti-
tative reverse transcription polymerase chain reaction.
Expression analysis was performed by Sapere Bio (formerly
HealthSpan Dx), using technology described previously (29). Every
run included external and internal controls to monitor assay per-
formance. Cycle threshold values over 37 were considered below
detection and excluded from the analysis. The overall precision
(reproducibility based on run-to-run and between operators’ ana-
lytical validation) of p16INK4a measurement was 0.8 Ct. The same
assay and quality control procedures were used for all samples.
Statistical Analysis
Descriptive statistics are provided to summarize the study sam-
ple. Differences in age by regimen were compared using ANOVA,
and paired t tests evaluated changes in p16INK4a expression over-
all and within each regimen. Linear regression was used to
model the relationship between patient characteristics with the
change in p16INK4a expression. Fisher exact test compared the
rates of p16INK4a expression change by regimen. All analyses
were conducted using SAS statistical software v9.4 (Cary, NC).
Conversion of change in log2 p16 to years of chronologic aging
was calculated using the formula: Dlog2p16/0.028 derived from a
633-patient cohort (32). All statistical tests were 2-sided, and a P
value of less than .05 was considered statistically significant.
Results
Patient Characteristics
We enrolled 146 patients diagnosed with early stage breast can-
cer who received neoadjuvant or adjuvant chemotherapy. Their
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baseline characteristics are presented in Table 1. The mean age
was 57 years (range ¼ 28-81). Karnofsky Performance Status was
greater than 80% in 92% of patients. African American patients
comprised 15.8% of the cohort, 50.7% had hormone receptor-
positive and HER2-negative tumors, and 62.3% were treated
with adjuvant chemotherapy. Nearly half the patients (47.9%)
were treated with anthracycline-based regimens (AC-T or AC-
TC), 34.9% with docetaxel and cyclophosphamide (TC), and
17.1% with docetaxel and carboplatin þ anti-HER2-directed
therapy (TCH). Radiation therapy was administered to 73% of
patients after the completion of chemotherapy. As shown in
Table 2, patient characteristics were closely associated with the
different chemotherapy regimens. For example and as
expected, patients with higher stage cancers (stage II and III)
were more likely to receive anthracycline (AC)–containing che-
motherapy, whereas TC was more likely administered in
women with estrogen receptor–positive tumors and lower stage
tumors; the majority of women receiving AC-TC had triple-
negative breast cancer.
Change in p16INK4a Expression From Baseline to
Posttreatment
Mean differences in p16INK4a expression from baseline to the
follow-up visit are presented in Table 3. Overall, chemotherapy
regimens were associated with a 1.4-fold increase in p16INK4a
expression (equivalent to a 17-year acceleration in aging; P <
.001). Anthracycline-based regimens (AC-T or AC-TC) were asso-
ciated with the largest mean change in p16INK4a expression (1.6-
to 1.7-fold increase; equivalent to a 23- to 26-year acceleration
in aging; P  .008), whereas smaller mean changes in p16INK4a
expression were observed in patients receiving nonanthracy-
cline chemotherapy regimens: TCH (equivalent to a 9-year ac-
celeration in aging; P ¼ .03) or TC (equivalent to 11-year
acceleration in aging; P ¼ .15).
Baseline p16INK4a and Change in p16INK4a Expression
Having established that the increase in p16INK4a expression may
be driven by the type of chemotherapy regimen, we tested if pa-
tient characteristics contributed to the magnitude of
chemotherapy-induced increase in p16INK4a expression.
Surprisingly, we found that baseline p16INK4a expression, and
not chronologic age, correlated with the magnitude of
chemotherapy-induced increase in p16INK4a expression
(Figure 1). When we separated the cohort into patients receiving
anthracycline- vs nonanthracycline-based chemotherapy, the
regression slopes of association between baseline p16INK4a ex-
pression and chemotherapy-induced change in p16INK4a expres-
sion were parallel between treatment groups (Figure 2, A).
These findings suggest that although anthracycline-containing
chemotherapy regimens cause larger increases in p16INK4a




Overall age at consent, y




African American 23 (15.8)
Other 13 (8.9)





Hormone receptor–positive and HER2-negative 74 (50.7)
Hormone receptor–negative and HER2-negative (triple negative) 42 (28.8)
HER2-positive and hormone receptor–negative 14 (9.6)
HER2-positive and hormone receptor–positive 16 (11.0)




Treatment regimens, No. (%)
AC-T (doxorubicin and cyclophosphamide then paclitaxel and
carboplatin)b
53 (36.3)
AC-TC (doxorubicin and cyclophosphamide then paclitaxel and
carboplatin)c
17 (11.6)
TC (docetaxel and cyclophosphamide)d 51 (34.9)
TCH (docetaxel and carboplatin þ anti-HER2 therapy)e 25 (17.1)
aAmerican Joint Committee on Cancer stage version 7.
bNine patients had paclitaxel before doxorubicin and cyclophosphamide. Doxorubicin and cyclophosphamide given every 2 weeks with growth factors (5 patients got
anthracycline every 3 weeks); 3 patients received anti-HER2 therapy with AC-T.
cTC given first in 11 patients.
dGiven every 3 weeks with growth factors; 2 patients received anti-HER2 therapy with TC.
eGiven every 3 weeks with growth factors; all received trastuzumab, and 19 patients received pertuzumab in addition to trastuzumab.
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expression levels than nonanthracycline regimens, the propen-
sity to increase p16INK4a expression was dependent on the base-
line p16INK4a expression and not an individual regimen.
Breast or locoregional radiation in this cohort was given to
73% of patients. There was no statistically significant difference
in the anthracycline chemotherapy–induced increase in
p16INK4a expression compared with those who did not receive
radiation therapy (P ¼ .29). As shown in Figure 2, B, regardless of
whether patients received radiation or not, a similar trend was
observed for an inverse correlation between p16INK4a expression
levels at baseline, and the magnitude of chemotherapy-induced
change in p16INK4a expression. A more detailed quantitative
analysis of the impact of radiation on the chemotherapy-
induced increase in p16INK4a expression was not possible, be-
cause there was a statistical interaction between baseline
p16INK4a expression and receipt of radiation (p16*radiation, P ¼
.06). This finding is not surprising because the decision to ad-
minister radiation is based on the type or surgery (partial or to-
tal mastectomy) and stage.
To understand the effect of baseline p16INK4a expression,
chemotherapy regimen, and race on the chemotherapy-
induced increase in p16INK4a expression, we analyzed these vari-
ables using univariate and multivariate regression analyses. As
shown in Table 4, in a multivariate analysis, both baseline
p16INK4a expression and chemotherapy regimen, but not race,
were statistically significant predictors of a chemotherapy-
induced increase in p16INK4a expression. These findings suggest
that patients with lower baseline levels of p16INK4a expression
are more likely to experience larger chemotherapy-induced
increases in p16INK4a expression.
Finally, to better understand how these data might apply to
a clinical setting, we evaluated whether specific chemotherapy
regimens differed in their propensity to increase p16INK4a ex-
pression (Figure 3). Changes in p16INK4a expression were
categorized as follows: increase in p16INK4a expression above the
assay precision (an increase over 0.4); unchanged p16INK4a levels
within the assay precision (between 0.4 and -0.4); and decrease
in p16INK4a expression below the assay precision (below 0.4).
Most patients had increases in p16INK4a expression, with percen-
tages ranging from 49% for the TC group to 71% for the AC-TC
group. The percentage of patients whose p16INK4a expression
remained unchanged ranged from 12% in the AC-TC group to
about 35% in both the AC-T and TC groups. Only a small per-
centage of patients (6%) in the AC-T had decreases in
chemotherapy-induced p16INK4a expression, but this rose to
16%-18% in the other 3 chemotherapy groups. Therefore, al-
though a choice of chemotherapy regimens may impact the
magnitude of chemotherapy-induced increase in p16INK4a ex-
pression, an increase in p16INK4a expression is likely driven by
the baseline p16INK4a expression and not chronological age or
other patient and tumor characteristics.
Discussion
We have previously shown that anthracycline-based chemo-
therapy in women with early stage breast cancer induced ex-
pression of cell senescence biomarkers in vivo (29). In the
current study, we determined if chemotherapy regimens com-
monly used in patients with early stage breast cancers have dif-
ferential effects on p16INK4a expression. We found that
anthracycline-based therapies were statistically significantly
more pro-aging than nonanthracycline-based therapies.
Adjuvant anthracycline-based chemotherapy regimens save
the lives of many patients and lower their risk of breast cancer
relapse and death (33). However, potential toxicities such as
myelodysplasia, acute leukemia (34,35) and cardiac toxicity (36)
detract from the overall benefit. For many breast cancer
Table 2. Patient characteristics by chemotherapy regimen
Variable
Regimen
AC-T AC-TC TC TCH
Pa
P
(n¼ 53) (n¼ 17) (n¼ 51) (n¼ 25) AC vs non-ACa
Chronological age, y
Mean (SD) 55.7 (11.5) 48.9 (12.5) 60.5 (11.3) 58.0 (13.1) .005 .006
Race, No. (%)
African American 12 (22.6) 2 (11.8) 4 (7.8) 5 (20.0) .48 .35
White 37 (69.8) 14 (82.3) 42(82.4) 17 (68.0)
Other 4 (7.5) 1 (5.9) 5 (9.8) 3 (12.0)
Phenotype, No. (%)
Estrogen receptor–positive 36 (67.9) 1 (5.9) 39 (76.5) 14 (56.0) <.001 .04
Estrogen receptor–negative 17 (32.1) 16 (94.1) 12 (23.5) 11 (44.0)
Stage, No. (%)
I 7 (13.2) 1 (5.9) 22 (43.1) 2 (8.0) <.001 <.001
II 27 (50.9) 10 (58.8) 29 (56.9) 15 (15.0)
III 19 (35.8) 6 (35.3) 0 (0) 8 (32.0)
Timing of chemotherapy, No. (%)
Adjuvant 29 (54.7) 2 (11.8) 49 (96.1) 11 (44.0) <.001 <.001
Neoadjuvant 23 (43.4) 15 (88.2) 2 (3.9) 14 (56.0)
Both 1 (1.9) 0 (0) 0 (0) 0 (0)
Radiation postchemotherapy, No. (%)
Yes 40 (75.5) 13 (76.5) 35 (68.6) 18 (72.0) .73 .29
No 13 (24.5) 4 (23.5) 16 (31.4) 7(28.0)
aANOVA for age (continuous variable) and Fisher exact test for all categorical variables. All tests 2-sided. AC-T ¼ doxorubicin and cyclophosphamide then paclitaxel
and carboplatin; AC-TC ¼ doxorubicin and cyclophosphamide then paclitaxel and carboplatin; TC ¼ docetaxel and cyclophosphamide; TCH ¼ docetaxel and carbopla-
tin þ anti-HER2 therapy.
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patients, nonanthracycline-containing adjuvant chemotherapy
regimens are associated with similar improvements in disease-
free and overall survival as anthracycline regimens (37).
Therefore, choosing a chemotherapy regimen that has a smaller
impact on the chemotherapy-induced acceleration of aging
may prove to be important to minimize chemotherapy-induced
acceleration of morbidity and mortality.
Interestingly, although chemotherapy regimen type may
have been an important driver of the magnitude of change in
p16INK4a expression, baseline p16INK4a expression levels also
played a statistically significant role. Patients with lower
p16INK4a values at baseline experienced a larger chemotherapy-
induced increase in p16INK4a expression than patients with
higher baseline p16INK4a values, and that association remained
statistically significant even after adjusting for chemotherapy
regimen. One potential limitation of our study is a smaller sam-
ple size (between 17 and 53 patients in each regimen group).
Larger studies will improve the quantification of age accelera-
tion induced by different chemotherapy regimens. In addition,
similar effects of chemotherapy and irradiation on telomere
length have been reported (14-18). Also, measurement of addi-
tional biomarkers of aging that capture various molecular
mechanisms of aging, such as an increase in inflammation (the
measurement of the senescence-associated secretory pheno-
type) (10), epigenetic changes (19,20) (DNA methylation panels),
and changes in metabolism, may deepen our understanding of
processes affected by chemotherapy. Taken together, our
results suggest that the choice of chemotherapy regimen, as
well as the baseline “molecular age” of the patient, are impor-
tant factors that determine the pro-aging capacity of chemo-
therapy regimens.
Our observation that patients with lower baseline p16INK4a ex-
pression experience a larger increase in p16INK4a expression is
unexpected. One explanation is that there may be a threshold to
the number of senescent cells a tissue or organism can tolerate.
Whereas senescence protects from cellular damage-induced tu-
morigenesis, the accumulation of senescent cells is detrimental
to tissue function and regenerative capacity because of an in-
crease in inflammation and depletion of stem cells. In naturally
aged mice, the number of senescent cells has been reported as
1%-3% of total tissue (38,39), suggesting that the maximum num-
ber of senescent cells is capped and tightly controlled by the im-
mune system. We have previously found in a cohort of human
donors that p16INK4a expression levels in a population tend to
plateau, suggesting that there is a saturation threshold for the
accumulation of senescent cells in humans as well (40). Our data
in this study demonstrate that patients with lower baseline
p16INK4a expression experienced a larger increase in p16INK4a lev-
els during chemotherapy treatments than patients with higher
baseline p16INK4a expression, consistent with the observation
that p16INK4a expression may plateau later in life.
Much research remains to be done to characterize the corre-
lation between p16INK4a expression levels and human health.
Although a link between p16INK4a expression and mortality has
been demonstrated in animal models (41-43), a definitive link
between senescence levels and the clinical manifestation of ag-
ing and mortality in humans has not been established. A few
studies have begun to establish the correlation between p16INK4a
expression and predisposition to chemotherapy-induced toxic-
ities and the development of frailty. For example, we demon-
strated that high levels of p16INK4a correlated with
chemotherapy-induced adverse events, such as severe (grade 3
and 4) fatigue (44). In childhood survivors, chemotherapy-
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mortality have been well established, and new data suggest
that chemotherapy increased p16INK4a expression in a dose-
dependent manner and increased p16INK4a expression correlated
with increased frailty in this cohort (45). Studies are underway
to establish the correlation between p16INK4a expression and
multimorbidities and mortality in middle-aged adult cancer
patients as well as young adult childhood cancer survivors.
In addition to chemotherapy, radiation is also known to pro-
mote cellular senescence (46-49). In murine models, whole body
radiation is a major inducer of senescence and p16INK4a
expression (50). However, the effect of radiation on changes in
p16INK4a expression in women with early stage breast cancer is
less clear. In women with early stage breast cancers, radiation is
limited to the breast (in earlier stage patients) or the chest wall
and regional nodes (in women treated with mastectomy and
with larger tumors and/or positive axillary lymph nodes).
Because of the targeted tissue volume treated, radiation in breast
cancer patients is not likely to have the same effect as in murine
models. Our previous studies in early stage breast cancer
patients who received anthracycline-containing chemotherapy
did not find radiation to be a statistically significant contributor
to the chemotherapy-induced increase in p16INK4a expression,
and in a second larger cohort of patients not treated with chemo-
therapy, radiation had no effect on p16INK4a expression (29). In
the current study, 73% of patients received breast or locoregional
radiation. We are unable to clearly define the role, if any, of radi-
ation and p16INK4a expression because of statistical interaction
between variables, but we are able to demonstrate that the in-
verse correlation between baseline p16INK4a levels and the magni-
tude of chemotherapy-induced p16INK4a increases remain even in
women who did not receive radiation treatment. Larger studies
in cohorts of women who receive radiation only or chemother-
apy with radiation would be able to tease out individual contri-
butions of baseline p16INK4a expression, chemotherapy regimen,

































Figure 2. Patient’s expression levels of p16INK4a prior to chemotherapy are a major predictor of chemotherapy-induced change in p16INK4a mRNA expression.
Correlation between baseline p16INK4a expression and chemotherapy-induced change in p16INK4a expression in patients receiving anthracycline (blue line) or nonan-
thracycline-containing regimens (orange line) (A) or patients who received (lavender line) or did not received (green line) postchemotherapy radiation (B). AC ¼
anthracycline.
Table 4. Linear regression parameter estimates for the magnitude of
change in p16INK4a mRNA expression
Variable
Univariate Multivariablea
Estimate Pb Estimate Pb
Chronologic age at consent 0.006 .31 0.010 .09
Baseline p16INK4a mRNA expression 0.410 <.001 0.435 <.001
Regimen, AC vs non-AC 0.380 .008 0.325 .01
Race, African American vs all
others
0.224 .26 NS NS
aRegimen-adjusted analysis was based on AC- vs non-AC–containing regimens.
AC ¼ anthracycline.
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Figure 1. Chemotherapy-induced changes in p16INK4a mRNA expression correlate with baseline p16INK4a expression but not chronologic age. Correlation between chro-
nologic age (A) or baseline p16INK4a expression (B) and chemotherapy-induced change in p16INK4a expression. AC ¼ anthracycline; M ¼ regression slope; non-AC ¼ non-
anthracycline-containing; NS ¼ not statistically significant (P ¼ .32).
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Altogether, our findings suggest that the pro-aging effects of
chemotherapy regimens are mediated by the combined effects
of the type of chemotherapy regimen and the patient’s baseline
p16INK4a level. In addition, our data suggest that anthracycline
regimens, especially when used in younger patients, accelerate
biologic age. Adjuvant anthracycline-based chemotherapy regi-
mens save the lives of many patients and lower their risk of
breast cancer relapse and death (33,51). However, recent studies
show that adjuvant nonanthracycline regimens may be as ef-
fective as anthracycline-containing regimens for large numbers
of early stage patients (37). Our data provide additional support
for selection on nonanthracycline regimens in women with
early stage breast cancer unless the projected benefit for
anthracycline regimens is clearly associated with improved out-
comes (for example, women with triple-negative breast cancer
or those with hormone receptor–positive breast cancer with 4 or
more positive nodes). For those patients where anthracycline
regimens are preferred, the protective effects of lifestyle inter-
ventions such as exercise or pharmacologic agents (52,53) (eg,
senolytics) to retard accelerated aging effects in patients receiv-
ing chemotherapy are areas of intense interest requiring further
research.
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Chem otherapy regim en
AC-T AC-T C T C T C-H
n = 53 n = 17 n = 51 n = 25
 log2p16 No. (%) No. (%) No. (%) No. (%)
Increase from  baseline 32 (60) 12 (71) 25 (49) 13 (52)
Unchanged 18 (34) 2 (12) 18 (35) 8 (32)
Decrease from  baseline 3 (6) 3  (18) 8 (16) 4  (16)
Figure 3. Patients whose p16INK4a expression levels are increased by chemotherapy are not restricted to any 1 treatment. Distribution of patients whose p16INK4a levels
increased above assay precision is similar among chemotherapy regimens commonly used to treat early stage breast cancer patients.
S. S. Shachar et al. | 7 of 8
Data Availability
The data underlying this article will be shared on reasonable re-
quest to the corresponding author.
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